While data show that botulinum toxin and the anti-CGRP monoclonal antibodies share the best documentation for the prevention of CM, there is not much information that compares the effectiveness and safety between the two to discuss which is a more potent preventative. The gene discussed is CALCA; the disease is cutaneous mastocytosis.